Table 2.
Patient Characteristics at the Time of Transplantation
| Baseline Characteristics | Routine G-CSF + Plerixafor (n=76) | Just-in-Time Plerixafor (n=60) | P-value |
|---|---|---|---|
| Disease Histology | 0.23 | ||
| Myeloma | 45 (59%) | 30 (50%) | |
| Lymphoma | 31 (41%) | 30 (50%) | |
| DLBCL | 11(35%) | 9 (30%) | |
| HL | 9 (30%) | 7 (23%) | |
| MCL | 4 (13%) | 9 (30%) | |
| FL | 1 (3%) | 4 (13%) | |
| Others ψ | 6 (19%) | 1 (3%) | |
|
| |||
| Median age, years (range) | 61 (23–75) | 59 (22–75) | 0.48 |
|
| |||
| Male gender | 42 (55.3%) | 34 (56.7%) | 1.0 |
|
| |||
| Race Caucasian |
74 (97.4%) | 59 (98.3%) | 1.0 |
|
| |||
| Prior radiation | 14 (18.4%) | 12 (20%) | 0.83 |
|
| |||
| Lines of prior therapy Mean/Median (range) | 1.6/1 (1–4) | 1.8/2 (1–4) | 0.23 |
|
| |||
| Bone marrow cellularity Mean/Median (range) | 40/41 (10–90) | 40/41 (5–95) | 0.87 |
|
| |||
| Pre-transplant status* | |||
| Myeloma | |||
| CR+VGPR | 28 (61%) | 16 (53%) | 0.83 |
| PR | 18 (39%) | 13 (43%) | |
| SD | 0 | 1 (3 %) | |
| Lymphoma | |||
| CR | 20 (67%) | 18 (60%) | 0.48 |
| PR | 9 (30%) | 11 (37%) | |
| SD/RD | 1 (3%) | 1 (3%) | |
|
| |||
| KPS median (range) | 80 (70–100) | 80 (60–100) | 0.64 |
|
| |||
| HCT CI median (range) | 2 (0–6) | 2 (0–6) | 0.39 |
*
Percentages are that of the specific disease subgroup.
ψ
others included primary CNS lymphoma (2), T-cell rich B-cell lymphoma (1), angioimmunoblastic T-cell lymphoma (1) and T-cell lymphoma-NOS (2) and DLBCL skin type (1).
Abbreviations: G-CSF, granulocyte colony-stimulating factor; HL, Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; FL, follicular lymphoma; CR, complete remission; VGPR, very good partial response; PR, partial response; SD, stable disease; RD, refractory disease; KPS, Karnofsky performance score; HCT-CI, hematopoietic cell transplantation-specific comorbidity index.